Holen Sie sich die Stockscreener-App
6.63
0.76%
0.05
Vorhandelsmarkt:
6.23
-0.40
-6.03%
Scisparc Ltd Aktie (SPRC) Neueste Nachrichten
SciSparc Ltd.Ordinary Shares (NQ: SPRC - The Chronicle-Journal
SciSparc | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment) - Moomoo
Scisparc posts audited 2025 net loss of USD 12.56 million - Bitget
SciSparc : Amendment to Annual Report by Foreign Issuer (Form 20-F/A) - marketscreener.com
SciSparc Boosts NeuroThera Stake in C$5.4 Million Financing - TipRanks
SciSparc (NASDAQ: SPRC) backs NeuroThera in C$5.4M raise - Stock Titan
SciSparc funds NeuroThera Labs spinoff with CAD 5.4m financing round - AllSci
SciSparc invests C$2.7M in subsidiary NeuroThera financing By Investing.com - Investing.com
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6% - Moomoo
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 - GlobeNewswire
Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement - TheNewswire
SciSparc (SPRC) Gains 1.59% as Shares Hold Firm Above $6 Support ZonePut Call Ratio - vinanet.vn
SciSparc Ltd. (SPRC) Stock Price, News, Quote & History - Yahoo! Finance Canada
NeuroThera Labs Inc. Closes First Tranche of Non-Brokered Private Placement - NewMediaWire
NeuroThera Labs Inc. Closes First Tranche Of Non-Brokered Private Placement - TheNewswire
SciSparc Ltd. (SPRC) stock price, news, quote and history - Yahoo Finance UK
SciSparc Subsidiary NeuroThera Wins Japanese Patent for Novel Pain and Fever Therapy - TipRanks
SciSparc Ltd. (Nasdaq: SPRC) subsidiary gains Japanese patent on novel pain treatment combo - Stock Titan
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination - The Manila Times
SciSparc Subsidiary NeuroThera Receives Japanese Patent for 4-Aminophenol Combination Therapy - Quiver Quantitative
Japanese patent covers SciSparc subsidiary’s pain and fever combo - Stock Titan
NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination - TradingView
SPRC Stock Price, Quote & Chart - ChartMill
SciSparc (SPRC) Slips 0.87% to $6.87 as Biotech Stock Holds Above Key SupportTrend Continuation Trade - dars.gov.et
Scisparc Ltd (SPRC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Scisparc Ltd (SPRC) Stock News Today - TradingKey
SciSparc’s NeuroThera Launches Phase IIb Tourette Trial at Yale Child Study Center - TipRanks
SciSparc (Nasdaq: SPRC) launches Phase IIb SCI-110 Tourette study - Stock Titan
SciSparc’s NeuroThera Opens Yale Site for Phase IIb SCI-110 Tourette Syndrome Trial - Quiver Quantitative
Tourette drug candidate enters Phase IIb with prior 21% tic reduction - Stock Titan
Price to book forward of SciSparc Ltd. – NASDAQ:SPRC - TradingView
SciSparc (SPRC) Slips Slightly as Shares Test Key Support Near $7.11Weak Sell Signals - vinanet.vn
SciSparc (SPRC) Plunges 18.16% — Support at $6.76 Becomes CriticalRegression Channel - Vinanet
SciSparc Announces NeuroThera Labs Achieves Milestone in Quantum-Enabled Clinical Trial Data Analytics Platform - Quiver Quantitative
Quantum clinical analytics milestone at SciSparc (Nasdaq: SPRC) - Stock Titan
SciSparc (SPRC) Drops 4.29% as Shares Test Key Support Near $8.26Retail Sentiment - dars.gov.et
Enterprise value to EBIT forward of SciSparc Ltd. – NASDAQ:SPRC - TradingView
SciSparc (SPRC) Surges Over 70%: Analyzing the Massive RallyHigh Volume Stocks - dars.gov.et
SciSparc Moves Into Agentic AI With New Scientific Advisory Board - TipRanks
Scisparc Ltd. Announces Establishment of Scientific Advisory Board - marketscreener.com
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum - GlobeNewswire
SciSparc (Nasdaq: SPRC) targets agentic AI, advances quantum platform - Stock Titan
Scisparc Ltd (SPRC) Earnings Date & Reports & Earnings News - TradingKey
Scisparc Ltd (SPRC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SciSparc shifts focus to agentic AI market - Investing.com
Scisparc Ltd (SPRC) Balance Sheet - TradingKey
Scisparc Ltd (SPRC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Scisparc Ltd (SPRC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Scisparc Ltd (SPRC) Institutional Confidence - TradingKey
SciSparc shifts focus to agentic AI market By Investing.com - Investing.com Canada
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity - The Manila Times
SciSparc targets agentic AI market and forms ad... - Pluang
Scisparc Ltd (SPRC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SciSparc Ltd. Targets Agentic AI Market and Plans Scientific Advisory Board for AI and Cybersecurity - Quiver Quantitative
SciSparc Announces Decision to Target the Agentic AI - GlobeNewswire
Scisparc Ltd (SPRC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Scisparc Ltd (SPRC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SciSparc Shares Decline 4.32%, Testing Key Support LevelsSingle Stock ETF - vinanet.vn
SciSparc Ltd. Revenue Breakdown – NASDAQ:SPRC - TradingView
SPRC|Scisparc Ltd|Price:5.330|Chg%:-0.390 - TradingKey
SciSparc Ltd. (SPRC) Experiences Sharp Decline: Key Support Levels in FocusGap Down Bounce Plays - vinanet.vn
SciSparc Company Profile & Introduction - Moomoo
Scisparc Ltd (SPRC) Income Statement - TradingKey
SciSparc (SPRC) Stock Forecast & Analyst Ratings - Moomoo
SciSparc(SPRC) Stock Options Chain | Quotes & News - Moomoo
SciSparc Ltd. (Nasdaq: SPRC) starts Phase IIb SCI-110 trial for Tourette - Stock Titan
NeuroThera starts Phase IIb trial in Germany fo... - Pluang
0.46%
2.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):